Introduction
The first oral direct-acting antivirals (DAAs) for treatment of hepatitis C virus (HCV) infection, the protease inhibitors telaprevir and boceprevir, were approved in 2011 [1] . Their antiviral efficacy was limited and they had to be combined with pegylated interferon (IFN) and ribavirin (RBV) and were associated with a high risk of serious adverse effects [2, 3] . The next generation of more potent and better tolerated DAAs was approved by the European Medicines Agency in 2014, and includes the polymerase inhibitor sofosbuvir, the NS5A replication complex inhibitor daclatasvir, and the protease inhibitor simeprevir [4] . Since then, additional DAAs from different drug classes have been approved [4] . IFN-free DAA combination therapy is now considered the standard of care for treatment of chronic hepatitis C, and DAAs are included in the WHO list of essential medicines (http://www.who.int/medicines/publications/ essentialmedicines/20th_EML2017_FINAL_amendedAug 2017.pdf?ua=1). HCV cure rates greater than 95% have been reported with similar treatment outcomes in both HCV-monoinfected and HIV/HCV-coinfected individuals [5] . Due to the negative impact of immunosuppression on progression of liver fibrosis, HIV/HCVcoinfected individuals are considered a group with high priority of HCV therapy [6] . However, the high market price of branded DAAs limits the access to this treatment even among some high-income countries [7] . Furthermore, there is a high variability in market prices for DAAs, particularly in high-income countries, with little correlation between drug prices and gross national income [8] . Although a marked increase since 2014 in uptake of DAAs among HIV/HCV individuals in Europe is anticipated, their use is expected to vary significantly across Europe, reflecting differences in affordability and prioritization within the healthcare systems as well as differences in the burden of liver fibrosis across Europe. In some countries and particular patient groups, IFNbased therapy might still be used. The aim of this study was to investigate regional differences in the rate of HCV treatment uptake, and type of therapy used among HIV/ HCV-coinfected patients in the pan-European Euro-SIDA study after 2011.
Methods
Study population and data collection Patients were included from the EuroSIDA study, a large prospective observational cohort of more than 22 000 HIV-1-positive patients followed in 100 hospitals in 35 European countries and Israel and Argentina (http:// www.chip.dk/Ongoing-Studies/EuroSIDA/About). Patients were enrolled into 10 cohorts from 1994 onwards.
In Cohorts 1-9, consecutive HIV-positive patients older than 16 years of age were enrolled irrespective of HCV status. In Cohort 10, all HIV-positive patients were also required to be positive for anti-HCV antibodies (HCV-RNA positive or negative). At recruitment, in addition to demographic and clinical data, a complete antiretroviral therapy (ART) history is obtained together with the most recent CD4
þ cell counts and HIV-RNA measurements, as well as anti-HCV, HCV-RNA, HCV genotype, hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV)-DNA. Data are collected prospectively at clinical sites and sent to the coordinating centre at 6 monthly intervals. At each follow-up visit, all CD4 þ cell counts, HIV-RNA, anti-HCV, HCV-RNA, genotype, HBsAg and HBV-DNA results measured since last follow-up are collected, and the start and stop dates for antiretroviral drugs and HCV and HBV drugs. Detailed information about data collected in EuroSIDA can be found at http://www. chip.dk/Ongoing-Studies/EuroSIDA/About.
All HCV-RNA-positive patients, with prospective follow-up after 1 January 2011 (when the first DAAs were introduced) were eligible for this study. Median last follow-up date was June 2016.
Classification of liver fibrosis stage
Liver fibrosis stage, according to the METAVIR classification [9] , was defined using data from liver biopsies, fibroscan, the aspartate aminotransferase to platelet ratio index (APRI) or from plasma hyaluronic acid, as previously described [10] . F4 fibrosis was defined from validated liver biopsy, fibroscan measurements greater than 12.5 kPa, an APRI score more than 2 and hyaluronic acid measurements more than 250 ng/ml. Fibrosis values at any given time point were the last values measured before the time point in question and in which more than one measurement of fibrosis was recorded on the same date, the biopsy was assumed to be the gold standard, followed by fibroscan, APRI then hyaluronic acid.
Hepatitis C virus treatment categories HCV treatment regimens were divided into three categories. First, IFN AE RBV (no DAA); second, DAA þ IFN AE RBV; and third, DAA AE RBV (no IFN).
Statistical analysis
Baseline was defined as the latest of 1 January 2011, recruitment to EuroSIDA, or testing HCV-RNA positive. Regions of Europe were classified as in previous studies [11] . Based on country of residence, people were grouped into five regions: West: Austria, Belgium, France, Germany, Luxembourg, Switzerland. South: Argentina, Greece, Israel, Italy, Portugal, Spain. North: Denmark, Finland, Iceland, Ireland, Netherlands, Norway, Sweden, United Kingdom. East Central: Bosnia-Herzegovina, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia, Slovenia. East: Belarus, Estonia, Georgia, Latvia, Lithuania, Russia, Slovakia, Ukraine.
Characteristics at last visit for those not starting HCV treatment during follow-up were compared with the characteristics at starting HCV treatment for those who started treatment during prospective follow-up. In those HCV-RNA positive, we calculated the incidence rate per 1000person-yearsoffollow-up(PYFU)forstartinganyHCV treatment during follow-up and starting IFN-free DAA therapy. This analysis included follow-up from baseline until last visit or first starting HCV treatment; patients may have been exposed to HCV treatment prior to baseline.
Poisson regression was used to determine the factors associated with starting IFN-free DAA during prospective follow-up. CD4 þ cell count, HIV viral load, starting combination ART (cART), starting IFN/RBV only treatment, AIDS diagnosis, diagnosis of AIDS within the last 12 months (recent AIDS), fibrosis stage, HCV-RNA level and HBsAg status were included as timeupdated variables. Other factors were fixed at baseline (sex, age, ethnic group, HIV transmission route, prior HCV treatment and CD4 þ nadir). All variables were included in multivariate models. In the Poisson regression model, Argentina was combined with Southern Europe, and 2011 and 2012 were combined as they had very similar incidence rate ratios (IRRs) of starting HCV treatment. HIV viral load was categorized as less than 500 and at least 500. CD4 þ cell count was analysed as two categories ( 350 and >350 cells/ml). Neither prior AIDS nor recent AIDS was associated with starting DAA and therefore only prior AIDS was included in the final multivariate model.
All analyses were performed using SAS version 9.4 (Statistical Analysis Software; Cary, North Carolina, USA).
Results
Incidence of starting any hepatitis C virus therapy A total of 4308 HCV-RNAþ HIV-positive persons were included in the study. Patient characteristics at time of starting hepatitis C virus therapy Table 1 shows the patient characteristics at time of starting any HCV treatment compared with last clinic visit in those untreated during follow-up. The median age of treated and untreated was 47 and 45 years, respectively, and around a third of all patients were HCV treatment experienced. Compared with untreated, HCV-treated patients were less likely to be women (23 vs. 30%), come from Central East (10 vs. 16%) and East (12 vs. 21%) and have a history of injection drug use (54 vs. 60%), but more likely to have genotype 1 (44 vs. 39%) and cirrhosis (22 vs. 11%). Treated persons were slightly more likely to have suppressed HIV-RNA (93 vs. 89%), whereas the median (IQR) CD4 þ cell count was similar [570 (401-770) vs. 548 cells/ml (364-773)]. The proportion of untreated patients with at least F3 was similar when comparing South (54%) with West (52%) and North (50%), but substantially lower than in Central East (86%) and East (79%). respectively. In East, uptake of HCV therapy was generally low in the entire study period and dominated by IFN þ RBV, although IFN-free therapy was used in almost 90% of those starting HCV treatment in 2016. Among 638 persons starting IFN-free treatment in 2015 and 2016, the most commonly used regimen was sofosbuvir/ledipasvir AE RBV (n ¼ 328, 51.4%) followed by ombitasvir/paritaprevir/ritonavir AE dasabuvir AE RBV (n ¼ 128, 20.1%) and sofosbuvir/daclatasvir AE RBV (n ¼ 108, 16.9%).
Use of different hepatitis C virus treatment regimens
Incidence of starting interferon-free direct-acting antiviral hepatitis C virus treatment A total of 638 (14.8%) persons started an IFN-free DAA regimen during 13 043 PYFU (median follow-up 2.3 years; IQR 1.3-5.1 years) with an overall incidence of 56.0/1000 PYFU (95% CI 51.9-60.0). The incidence of starting IFN-free DAA increased from 7.8/1000 PYFU (5.9-9.8) in 2014 or earlier to 135.2/1000 PYFU (122.0-148.5) in 2015 and 128.9/1000 PYFU in 2016 (113.5-144.3), and varied significantly across regions (Fig. 2) . The increase was highest in North and West and intermediate in South. From 2015 to 2016, the incidence decreased by 46% in South, whereas the incidence continued to increase in West and North. In both Central East and East there was a modest increase in incidence in use of DAAs in 2015 and 2016.
Within each region the uptake of IFN-free DAA varied substantially (Fig. 3) . For example in West, which included six countries each with at least 30 persons under follow-up in 2016, the use of DAA therapy varied from 4 to 62%. In East, uptake of DAA was less than 5% in four out of six countries. A notable exception is in Georgia where 31% have been treated with DAAs as part of a national hepatitis C elimination program paid for by Gilead Sciences [12] . Among the 16 countries which according to the study by Marshall et al. [7] had no restrictions for reimbursement of IFNfree DAA based on both fibrosis stage and recent drug/ alcohol dependence or that prioritized those HIV/ HCV-coinfected, the uptake of IFN-free DAA among persons under follow-up in 2016 was only 22.2% in all countries combined, and exceeded 40% in just four countries (France, Iceland, Netherlands and Slovenia).
Factors associated with starting interferon-free direct-acting antiviral treatment Figure 4 shows the We performed a number of sensitivity analyses, restricting included patients to either those with F3 or F4 fibrosis at baseline, or those with a history of IDU, or excluding MSM, or including only countries with no restrictions for reimbursement according to Marshall et al. [7] . In adjusted analysis, factors associated with starting IFN-free DAA therapy were very consistent and similar to the findings in the general analysis, although not all 
Discussion
Among 4308 HIV/HCV-coinfected persons followed in 35 European countries as well as Israel and Argentina, 26% started anti-HCV therapy between 2011 and 2016. The overall incidence of starting therapy remained relatively stable until 2014, but increased markedly in 2015. By 2014, IFN-free DAA therapy was the predominant anti-HCV regimen used in Western Europe. The uptake of IFN-free treatment did not start to pick up until 2015 in Central East and East, and remained significantly lower than in the other regions.
As effective cART against HIV infection became available 20 years ago, its uptake has been lower in Eastern Europe compared with Western Europe [13] . History is now repeating itself with regards to effective and well tolerated anti-HCV therapy. Although several DAAs have been granted market authorization in the countries in East, prescription of the drugs are restricted by their high prices and lower purchasing power in this part of Europe [14] . Both Gilead Sciences [15] and Bristol-Myers Squibb [16] have signed licence agreements that allow generic manufacturing of sofosbuvir/ledipasvir and daclatasvir for sale in more than 100 low-income and middleincome countries. However, among the countries in the EuroSIDA East region none are included in the access plans. Hence, HCV-infected persons in general from this region have very limited access to DAAs via their healthcare system. The more affluent patients will be able to get DAAs outside the national healthcare system by buying generic DAAs directly from other countries or from buying them on the internet. One notable exception is in Georgia that since April 2015 has had a national hepatitis C elimination program where all HCVinfected persons are offered DAA therapy paid for by Gilead Sciences [12] . Despite unrestricted access to free DAA, only 30% of Georgian patients included in this study had started treatment.
Our study also documented large intraregional variations in uptake of DAAs. Even though restrictions on reimbursement for DAAs have been removed gradually in many European countries during the study period [7] , treatment uptake remained modest, even within countries with no reimbursement restrictions, although the numbers should be interpreted cautiously due few individuals under follow-up in some countries. The WHO has set a goal of eliminating HCV infection as a public healthcare threat by 2030 and recommends that all HIV/HCV-coinfected persons are given effective treatment for both infections as a priority [17] . Our data indicate that by 2016 only few European countries are on track to achieve this goal.
The incidence in uptake of DAA-based therapy continued to increase from 2015 to 2016 in all regions except South where it decreased by 46%. The reason for this sharp drop is unclear, but could be due to a 'warehousing effect' in which the high incidence in 2014 and 2015 was driven by large groups of patients who had waited for the introduction of effective therapy leaving fewer eligible for therapy in the remaining cohort.
In 2015/2016, 9% of all treatment regimens were IFN þ RBV. The uptake of IFN þ RBV was restricted to 16 countries from all regions of EuroSIDA and used for all genotypes. IFN þ RBV were until recently the recommended regimen for treatment of acute HCV infection [6] . with lower stages of fibrosis, 11% of untreated persons had signs of cirrhosis, and hence are at increased short-term risk of liver-related complications if they do not get access to effective HCV treatment. Reasons for not starting therapy are not collected in EuroSIDA, but in addition to nonavailability of anti-HCV drugs, comorbidities, ongoing illicit drug or alcohol abuse and other causes of unstable life circumstances perceived to be associated with nonadherence to therapy are likely reasons for not starting therapy.
Women were also less likely to receive DAA therapy than men, even after adjustment for other factors associated with starting therapy. Large trials have found no differences in effectiveness and safety of DAAs according to sex [18, 19] . An earlier EuroSIDA study on the uptake of HCV treatment in the IFN era, found no differences according to sex [20] . The sex difference was most pronounced among those younger than 35 years of age, and was consistent across regions and in all sensitivity analyses. There were no sex differences in use of cARTor proportion with suppressed HIV-RNA, but women had slightly longer times between CD4 þ and HIV-RNA measurements which might suggest less frequent clinic visit. DAAs are generally contraindicated during pregnancy and breastfeeding [21] , but given the short duration of DAA therapy and the age distribution of the cohort, the effect of pregnancy on DAA uptake seems minimal. Residual confounding cannot be excluded.
An important, but not unexpected finding was that lack of engagement in HIV care (defined as not receiving cART or having unsuppressed HIV-RNA) was associated with lower incidence of starting DAA. Hence, barriers in the HIV care continuum are linked to poorer outcomes in HCV care and should be addressed in a concerted manner to improve outcomes for both infections. There was a trend towards a lower incidence of DAA uptake among persons with a history of IDU, although it did not reach statistical significance. Studies have confirmed that DAAs are effective among IDUs and guidelines recommend that all HCV-infected persons, including IDUs, should be considered for therapy [6, 22] .
Study limitations
The current study has some limitations that should be mentioned.
Although EuroSIDA seeks to include a representative sample of participants from all European countries, participants are mainly recruited from university clinics in large European cities and not in exact proportion to the infected population in each country, and may therefore not be representative of the entire HIV/HCV-coinfected population in Europe. Among all anti-HCV-positive individuals followed up after 2011, 1273 (17.9%) have unknown HCV-RNA status (not tested or not reported). Both factors might have led us to overestimate the incidence of HCV treatment, particularly in East where 710/1670 (42.5%) of all anti-HCV-positive persons had unknown HCV-RNA. In the majority of participants, staging of liver fibrosis was based on APRI. Compared with liver biopsy, APRI is known to misclassify the fibrosis stage in some individuals, particularly in those with intermediate stage of fibrosis [23] . Furthermore, we not able to analyse the role of missed visits and/or frequency of visits for HIV care. The major strengths of this study is that it prospectively follows a large population of coinfected persons in a heterogeneous real-life setting across all regions of Europe, and that we have longitudinal data collected in a standardized way to allow temporal changes to be described.
Conclusion
Although the use of effective and well tolerated DAAs against HCV have increased markedly among HIV/ HCV-coinfected patients in Europe in general since 2014, cost of the drugs and other barriers to treatment prevent them from reaching some of the patients most at need of HCV treatment. Further follow-up to monitor access to DAA therapy to achieve the WHO HCV elimination goal in 2030 among HIV/HCV-coinfected in Europe is warranted.
